Standalone quarter ended September 30, 2026: revenue up 3.2%, profit after tax down 42%
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 19.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Standalone quarter ended September 30, 2026: revenue from operations was INR 2,062.97 million, up 3.2% from INR 1,998.33 million, but profit after tax was INR 292.50 million, down 42.0% from INR 504.27 million. EBITDA before other income, interest, depreciation and tax fell to INR 454.02 million from INR 726.47 million, narrowing the margin to 22.0% from 36.4%. There were no exceptional items in the quarter.
Profit fell 42% and EBITDA margin narrowed 14.3 percentage points, which may weigh on sentiment and the share price despite a 3.2% revenue rise.
The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.